Stay updated on Pembrolizumab Combo in Resectable NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page
- Check3 days agoChange DetectedA recruitment-status indicator was added, signaling that the study is no longer recruiting participants. Additionally, new navigation/help items were added, the Interventions header formatting was standardized to Intervention/Treatment, and the revision tag was updated from v3.5.5 to v3.6.0.SummaryDifference0.1%

- Check11 days agoChange DetectedRevision: v3.5.5 was added, replacing Revision: v3.5.4 on the page metadata.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe page's revision tag was updated to v3.5.4 and the previous v3.5.3 tag was removed, signaling a small update to the page’s revision history.SummaryDifference0.0%

- Check39 days agoChange DetectedTaoyuan District, Taiwan, 333 was removed and Taoyuan, Taiwan, 333 was added to the study locations in Taiwan. This updates the geographic coverage and enrollment options for participants in that region.SummaryDifference0.0%

- Check46 days agoChange DetectedThe page now displays revision v3.5.3, replacing the previous v3.5.2. This reflects a version update rather than a change to trial content.SummaryDifference0.0%

- Check53 days agoChange DetectedCity location text for Bucharest, Romania changed from the Romanian spelling (“București”) to the English spelling (“Bucharest”) while keeping the same address entry.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in Resectable NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.